1) 非営利機関以外の利用者は事前に<a href= 'http://ips-cell.net/j/index.php' target="_blank">iPSアカデミアジャパン株式会社 </a>から確認書を得ること。2) <a href='http://cell.brc.riken.jp/ja/wp-content/uploads/restriction/non-profit_j.pdf' target="_blank">別紙1 (非営利) </a>または<a href='http://cell.brc.riken.jp/ja/wp-content/uploads/restriction/profit_j.pdf' target="_blank">別紙1 (営利) </a>を提供同意書 (C-0003またはC-0003p) に添付すること。3) 先ずは、<a href="mailto:cellips.brc@riken.jp?subject=Disease specific iPS cell line 問い合わせ&">理研細胞バンク</a>にお問い合わせください 。
Disease specific iPS cell line derived from a patient : Dravet syndrome, heterozygous mutation of SCN1A. HPS1460, HPS1461, HPS1462, HPS1463, HPS1464, HPS1465 were derived from the same patient. Order Form (C-0042, C-0007 or C-0007p).
1) In relation to the for-profit organizations, please contact <a href= 'http://ips-cell.net/e/index.php' target="_blank">iPS Academia Japan, Inc.</a>, prior to the utilization of iPS cells. 2) Attach <a href='http://cell.brc.riken.jp/en/wp-content/uploads/restriction/non-profit_en_j.pdf' target="_blank">TERMS and CONDITIONS (non-for-profit) </a> or <a href='http://cell.brc.riken.jp/en/wp-content/uploads/restriction/profit_en_j.pdf' target="_blank">TERMS and CONDITIONS (for-profit) </a> to MTA (C-0007 or C-0007p) . 3) Contact Us : <a href="mailto:cellips.brc@riken.jp?subject=Disease specific iPS cell line&">RIKEN Cell Bank</a>
Disease specific iPS cell line derived from a patient : Dravet syndrome, heterozygous mutation of SCN1A. HPS1460, HPS1461, HPS1462, HPS1463, HPS1464, HPS1465 were derived from the same patient.
HPS1460
HPS1460
疾患特異的iPS細胞株。ドラベ症候群患者の末梢血単核球にエピゾーマルベクターを用いてOCT3/4, SOX2, KLF4, L-MYC, LIN28, mp53DD, EBNA1を導入して樹立。
Disease-specific iPS cells. iPS cells were established from the peripheral blood mononuclear cells of Dravet syndrome patient using episomal vectors encoding OCT3/4, SOX2, KLF4, L-MYC, LIN28, mp53DD and EBNA1.
疾患特異的iPS細胞株。ドラベ症候群、SCN1Aヘテロ型患者由来。HPS1460, HPS1461, HPS1462, HPS1463, HPS1464, HPS1465は同一人由来。Feeder free培養。緩慢冷却法保存。